Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2023-01-25 Director's Dealing
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Updates
Director's Dealing Classification · 95% confidence The document is extremely short (112 characters) and contains a table with transaction dates and share quantities, indicating a report of personal share transactions by company directors or executives. There is no detailed financial data or broader context, so it is not a full financial report or announcement. This matches the definition of Director's Dealing (DIRS).
2023-01-25 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued by a registrar and transfer agent (Link Intime India Pvt. Ltd.) under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. It confirms the processing of securities dematerialisation requests for the quarter ended 31 December 2022. The document is a compliance certificate and does not contain financial data, management discussion, or report content. It is primarily a regulatory compliance confirmation letter, which fits the definition of a Regulatory Filing (RNS) rather than a financial report or announcement of a report. The document length is short (1689 characters), and it is not an announcement of a report publication but a certificate confirming regulatory compliance.
2023-01-09 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Beta Drugs Limited for the first half of fiscal year 2023 (H1 FY23). It includes management's opening remarks, financial performance highlights, business segment updates, growth strategies, and a Q&A session with analysts. The presence of detailed financial figures, discussion of revenue, EBITDA margins, profit after tax, and business outlook confirms this is a full transcript of a quarterly earnings call. The document length is about 15,000 characters, consistent with a full call transcript rather than a brief earnings release or summary. Therefore, the appropriate classification is Call Transcript (CT).
2022-11-07 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-10-29 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation H1’ 2022-23' and contains detailed financial performance data, business highlights, growth metrics, future roadmap, and strategic plans. It includes revenue, EBITDA, PAT figures, solvency ratios, and market expansion strategies. The content is typical of a presentation aimed at investors, focusing on financials, strategy, and market positioning rather than a formal regulatory filing or report. There is no indication that this is an official annual or interim report, audit report, or earnings release. The length (15,000 characters) and detailed content support it being a full investor presentation rather than a brief announcement or certification. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-10-28 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on 27th October 2022 by Beta Drugs Limited. It includes approval of unaudited standalone and consolidated financial results for the half year ended 30th September 2022, along with a limited review report. The document contains Management Discussion & Analysis, unaudited financial results, and a limited review report by auditors. The presence of interim financial data for a half-year period, detailed financial tables, and management commentary indicates this is a comprehensive interim financial report. It is not merely an announcement of a report or a certification, but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2022-10-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.